Regor Therapeutics

Regor Therapeutics is a clinical stage biotech developing medicines using the proprietary CARD Platform in oncology, immunology, and metabolic disorders. 

Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand
Biotech

Genentech pays $850M upfront for Regor's CDK inhibitors

Genentech is taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in patients failed by existing options.
Nick Paul Taylor Sep 30, 2024 5:30am
Pfizer

Regor notches minor victory in trade secrets feud with Pfizer

Feb 8, 2023 9:30am
drug lawsuit

Former Pfizer employees countersue in trade secrets dispute

Mar 23, 2022 10:55am